Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07735533
PHASE1/PHASE2

A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies

Sponsor: Umoja Biopharma

View on ClinicalTrials.gov

Summary

This study is a Phase 1/2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed/refractory B-cell malignancies, including large B-cell lymphoma (LBCL).

Official title: A Phase 1/2, Open-label, Multicenter Study of UB-VV400 With Rapamycin in Relapsed or Refractory B-cell Malignancies

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

274

Start Date

2026-08

Completion Date

2031-08

Last Updated

2026-07-30

Healthy Volunteers

No

Interventions

GENETIC

UB-VV400

UB-VV400 is a gene therapy that generates CD22-directed CAR T cells in the body.

DRUG

Rapamycin (sirolimus)

Rapamycin is a drug approved by the FDA for indications unrelated to cancer.